MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH Has $37.12 Million Stock Position in Kenvue Inc. (NYSE:KVUE)

MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH lowered its stake in Kenvue Inc. (NYSE:KVUE - Free Report) by 5.2% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,548,121 shares of the company's stock after selling 84,463 shares during the period. MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH owned approximately 0.08% of Kenvue worth $37,124,000 as of its most recent filing with the SEC.

Other hedge funds also recently modified their holdings of the company. SRS Capital Advisors Inc. increased its position in shares of Kenvue by 67.4% in the fourth quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company's stock worth $30,000 after purchasing an additional 571 shares during the period. Asset Planning Inc bought a new position in Kenvue in the fourth quarter valued at about $42,000. Clarity Asset Management Inc. bought a new position in Kenvue in the fourth quarter valued at about $45,000. SBI Securities Co. Ltd. bought a new position in Kenvue in the fourth quarter valued at about $46,000. Finally, Deseret Mutual Benefit Administrators grew its position in Kenvue by 29.0% in the fourth quarter. Deseret Mutual Benefit Administrators now owns 2,528 shares of the company's stock valued at $54,000 after acquiring an additional 568 shares during the last quarter. Institutional investors own 97.64% of the company's stock.

Kenvue Trading Down 2.7%

Shares of KVUE stock traded down $0.60 during mid-day trading on Friday, reaching $21.44. 37,242,399 shares of the stock traded hands, compared to its average volume of 16,489,867. The stock's fifty day simple moving average is $23.03 and its two-hundred day simple moving average is $22.49. Kenvue Inc. has a 1-year low of $17.67 and a 1-year high of $25.17. The company has a market cap of $41.14 billion, a price-to-earnings ratio of 40.46, a price-to-earnings-growth ratio of 2.62 and a beta of 0.98. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66.

Kenvue (NYSE:KVUE - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported $0.24 EPS for the quarter, topping analysts' consensus estimates of $0.23 by $0.01. The company had revenue of $3.74 billion for the quarter, compared to analyst estimates of $3.69 billion. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. The firm's quarterly revenue was down 3.9% on a year-over-year basis. During the same period in the previous year, the firm earned $0.28 earnings per share. On average, research analysts anticipate that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, May 28th. Investors of record on Wednesday, May 14th were paid a $0.205 dividend. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.82%. The ex-dividend date of this dividend was Wednesday, May 14th. Kenvue's dividend payout ratio is currently 149.09%.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the company. Redburn Atlantic assumed coverage on Kenvue in a research report on Thursday, April 10th. They issued a "neutral" rating and a $23.50 target price on the stock. Barclays lifted their target price on Kenvue from $22.00 to $23.00 and gave the company an "equal weight" rating in a research report on Monday, May 12th. Evercore ISI assumed coverage on Kenvue in a research report on Monday, March 24th. They issued an "in-line" rating and a $25.00 target price on the stock. Canaccord Genuity Group lifted their target price on Kenvue from $24.00 to $29.00 and gave the company a "buy" rating in a research report on Wednesday, March 5th. Finally, Citigroup lifted their target price on Kenvue from $22.00 to $24.50 and gave the company a "neutral" rating in a research report on Friday, May 9th. Seven investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, Kenvue presently has a consensus rating of "Hold" and an average price target of $25.33.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.